Prognostic benefit of POLE exonuclease domain mutations in endometrial cancer cannot be explained by increased sensitivity to adjuvant treatment strategies - Van Gool, I; Rayner, E; Osse, E; Tomlinson, I; Smit, V; Creutzberg, C; Church, D; de Wind, N; Bosse, T; Drost, M (Wolters Kluwer, 2017)